TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7986518
Drug: Sublingual clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual clonidine 0.3 mg
Study: 7986518
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 0.3 mg
Study: 2493098
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg mitomycin C with 200,000 units hyaluronidase
Study: 2493098
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg mitomycin C alone
Study: 30300020
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) therapy, 4 sessions of 29J/cm2 at 3 weekly intervals
Study: 30300020
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheet (SGS), applied over the other half of the scar and changed at 3 weekly intervals
Study: 29364096
Drug: Levofloxacin containing
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin containing sequential therapy with bismuth
Study: 29364096
Drug: Levofloxacin containing
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin containing sequential therapy
Study: 2566778
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg twice daily)
Study: 23099620
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg twice daily) + Itraconazole (200 mg once daily)
Study: 20225473
Drug: Collagenase solution
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase solution
Study: 20225473
Drug: Esterase solution
Normalized name: cocaine esterase
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterase solution
Study: 20225473
Drug: Phosphate buffer
Normalized name: PHOSPHATE BUFFERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffer solution
Study: 10657767
Drug: Broad spectrum
Normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad spectrum herbal therapy ointment (BSHT) at 1% v/v
Study: 8478306
Drug: Dirithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (500 mg once daily for 5-7 days)
Study: 8478306
Drug: Miocamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miocamycin (600 mg twice daily for 5-7 days)
Study: 3021498
Drug: Nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil sodium, 4 mg four times daily
Study: 29996476
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (400 mg of magnesium oxide daily)
Study: 27613505
Drug: Varenicline (0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5mg BID × 5 doses)
Study: 12270988
Drug: Mupirocin (thrice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin (thrice-weekly application)
Study: 12270988
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ointment)
Study: 2195734
Drug: cyclosporin (Cs)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin (Cs) treatment for one year
Study: 2195734
Drug: cyclosporin (Cs)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin (Cs) treatment for three months
Study: 2195734
Drug: cyclosporin (Cs)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin (Cs) treatment for twelve months
Study: 2195734
Drug: cyclosporin (Cs)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin (Cs) treatment
Study: 154624
Drug: Arecoline (cholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline (cholinergic agonist)
Study: 31195828
Drug: 1-day Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day Acceptance and Commitment Therapy workshop
Study: 28158981
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication availability
Study: 26232911
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g of low-fat lamb per day
Study: 26232911
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g of high-fat lamb per day
Study: 23957603
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Ecologic 825, Winclove, Amsterdam, the Netherlands) for 8 weeks after 4 weeks of antibiotics
Study: 23957603
Drug: Antibiotics or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics or probiotics
Study: 15863861
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.1% adapalene gel + 5% benzoyl peroxide
Study: 7447218
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of methylprednisolone, intravenously, once a month for 6 months
Study: 24608310
Drug: 4-L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-L PEG solution
Study: 17716288
Drug: Lipo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipo Cream
Study: 17716288
Drug: Lipo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipo Ointment
Study: 11756949
Drug: Tacrolimus (FK506)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (FK506) 0.1% ointment
Study: 956798
Drug: Therapist self-reported
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist self-reported behavioral arousal during therapy
Study: 956798
Drug: Physiological activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological activation during therapy (measured by electromyogram, heart rate, blood pressure, skin conductance)
Study: 26608727
Drug: Direct access
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct access to low-dose computed tomography (LDCT) from primary care combined with a 1 h lung cancer update meeting.
Study: 22761006
Drug: Trans-dermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-dermal nicotine patches and cognitive behavioral therapy (Group 1)
Study: 22761006
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy alone (Group 2)
Study: 16801465
Drug: Trandolapril (target,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (target, 4 mg/d)
Study: 12732391
Drug: Unopposed 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unopposed 17beta-estradiol administered for a 2-year treatment period
Study: 10819344
Drug: Cefpodoxime-proxetil, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime-proxetil, 8 mg/kg/day in two divided doses for 5 days followed by 5 days of placebo
Study: 10819344
Drug: Cefpodoxime-proxetil, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime-proxetil, 8 mg/kg/day in two divided doses for 10 days
Study: 10641772
Drug: CAPD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPD treatment
Study: 1797696
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg carteolol/day
Study: 6683554
Drug: Bifonazole cream
Normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole cream 1%, solution 1%, gel 1%, and powder 1% administered once daily for 2 or 3 weeks
Study: 29228436
Drug: Atomized inhalation
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomized inhalation of ipratropium bromide and budesonide suspension, oxygen flow 3-5 L/min, 15-20 min/time, twice a day for 1 week
Study: 29228436
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received routine treatment including saline through a ventilator mask
Study: 29228436
Drug: Atomized inhalation
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomized inhalation of ipratropium bromide and budesonide suspension
Study: 26435087
Drug: InterX5000 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: InterX5000 treatment
Study: 24354496
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/day for 4 weeks
Study: 24354496
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/day for 4 weeks
Study: 17890171
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering with perindopril/indapamide combination
Study: 26855107
Drug: Levonorgestrel contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel contraceptive implant (150 mg), initiated immediately
Study: 26855107
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3-month delay in implant initiation)
Study: 26855107
Drug: Levonorgestrel contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel contraceptive implant (150 mg)
Study: 18336399
Drug: 12 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of single-agent paclitaxel (175 mg/m(2) over 3 h every 28 days)
Study: 18336399
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of the same treatment regimen (paclitaxel)
Study: 18336399
Drug: 12-cycle maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-cycle maintenance program with baseline CA-125 level <or=10 units/mL
Study: 16181163
Drug: Haloperidol 1.5
Normalized name: haloperidol 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1.5 mg/d
Study: 12749512
Drug: Quetiapine (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (combined groups: 150, 300, 600, and 750 mg)
Study: 12749512
Drug: Haloperidol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (12 mg)
Study: 1984710
Drug: Alprazolam 0.25
Normalized name: alprazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.25 mg t.i.d. for 14 days
Study: 1984710
Drug: Buspirone 5
Normalized name: busPIRone 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 5 mg t.i.d. for 14 days
Study: 22984102
Drug: Control/no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/no treatment group (CG)
Study: 20636227
Drug: Red Yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Yeast Rice (RYR) - HypoCol, 4 capsules/day
Study: 14528656
Drug: H1‐receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1‐receptor antagonist (0.1 mg/kg BW dimetindene) plus H2‐receptor antagonist (5 mg/kg BW cimetidine) diluted with 100 ml 0.9% NaCl
Study: 14528656
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml 0.9% NaCl)
Study: 14528656
Drug: H1‐receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1‐receptor antagonist plus H2‐receptor antagonist
Study: 10632409
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection
Study: 30920646
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to bear treatment-related toxicities
Study: 27062270
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg/d)
Study: 29438157
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg/d) + Low-dose Naltrexone (25 mg/d)
Study: 22546895
Drug: Intravenous buspirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buspirone (0.3 mg)
Study: 22546895
Drug: Intravenous buspirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buspirone (1.0 mg)
Study: 21526663
Drug: Lateral position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral position (group L)
Study: 15821819
Drug: Intravenous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dalteparin
Study: 9931171
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes of brisk walking 5 to 7 times weekly for 12 weeks
Study: 2175139
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 or 4 mg in an iv bolus 10 min before insulin or smoking)
Study: 2175139
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 IU/kg in an iv bolus)
Study: 2175139
Drug: Dexamethasone alone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone alone (2 or 4 mg in an iv bolus)
Study: 7017189
Drug: L-Keflex
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Keflex
Study: 16673799
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% shampoo, treated once daily for 4 weeks, rinsed off after 15 minutes
Study: 16673799
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate gel, leave-on formulation
Study: 16673799
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate shampoo and gel
Study: 29796596
Drug: Recorded music
Normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recorded music listening (ML)
Study: 22155457
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg)
Study: 8911981
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg)
Study: 20082585
Drug: Technosphere inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere inhaled insulin
Study: 17640310
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir (900 mg daily for 21 days, then 900 mg daily for 28 days)
Study: 17640310
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg twice daily for 21 days)
Study: 12409329
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 micro g
Study: 31987116
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy diet containing 50 g of Kashk (intervention group)
Study: 30367257
Drug: Calcium hydroxide-based
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide-based intracanal medication (ICM) after 30 days
Study: 21941411
Drug: DHA 400
Normalized name: DuetDHA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 400 mg/day from 12th week gestation until 4 months postpartum
Study: 11133605
Drug: Remifentanil infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusions
Study: 9644229
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg, n=6; 100 mg, n=2; 120 mg, n=1)
Study: 2757891
Drug: Digoxin (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (inhibitor of the sodium/potassium pump)
Study: 2757891
Drug: Dipyridamole (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (inhibitor of the anion transporter)
Study: 2757891
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (oral load)
Study: 23499390
Drug: Enobosarm 1
Normalized name: enobosarm
DrugBank: Enobosarm (DB12078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enobosarm 1 mg
Study: 27138015
Drug: Enobosarm 3
Normalized name: enobosarm
DrugBank: Enobosarm (DB12078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enobosarm 3 mg
Study: 19553295
Drug: Lysine plus
Normalized name: Lysine Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine plus glucose (25 g glucose)
Study: 15987985
Drug: Gamma brachytherapy
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma brachytherapy with an iridium 192 source (14-Gy dose at 2 mm into the arterial wall)
Study: 12583947
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (n-3 PUFAs)
Study: 12583947
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil capsules (n-6 PUFAs)
Study: 1609951
Drug: Midazolam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.25 mg/kg
Study: 2110954
Drug: Midazolam 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.35 mg/kg
Study: 2110954
Drug: Midazolam 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.45 mg/kg
Study: 394555
Drug: Hyperbaric 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric 5% lidocaine with 75 mg/ml glucose concentration
Study: 394555
Drug: Hyperbaric 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric 5% lidocaine with 50 mg/ml glucose concentration
Study: 394555
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both hyperbaric 5% lidocaine solutions
Study: 30421023
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of imatinib therapy
Study: 30421023
Drug: Dasatinib treatment
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib treatment after molecular recurrence
Study: 30421023
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from diagnosis to discontinuation of imatinib therapy
Study: 30421023
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of imatinib therapy
Study: 22282101
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg estradiol
Study: 22282101
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg estradiol
Study: 22282101
Drug: 0.375 mg
Normalized name: vitamin A 0.375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375 mg estradiol
Study: 22282101
Drug: 0.27 mg
Normalized name: capsaicin 0.27 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.27 mg estradiol
Study: 21050549
Drug: Control (Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Traditional Chinese medicine or/and progesterone)
Study: 15703502
Drug: Atorvastatin 10-20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10-20 mg
Study: 15703502
Drug: Pravastatin 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20-40 mg
Study: 15703502
Drug: Branded simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Branded simvastatin 10-80 mg
Study: 15703502
Drug: Generic simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic simvastatin 40-80 mg
Study: 12213159
Drug: Daunorubicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (5 microg) intravitreal injection
Study: 7608243
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (30 mg intravenously every six hours for four doses)
Study: 7608243
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution, intravenously every six hours for four doses)
Study: 1695308
Drug: Isradipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (mean dose of 3.6 mg daily)
Study: 1695308
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean dose of 50 mg daily)
Study: 30971174
Drug: N-SORB (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-SORB (1 mL, twice daily)
Study: 25347938
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ipragliflozin once daily for 24 weeks
Study: 31607191
Drug: Mindfulness-based art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based art therapy (MBAT)
Study: 21366847
Drug: Aliskiren/HCTZ 150/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/HCTZ 150/12.5 mg
Study: 19197536
Drug: Oral liarozole
Normalized name: letrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liarozole (75 or 150 mg/day)
Study: 16492838
Drug: Amantadine sulfate
Normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine sulfate 100 mg
Study: 31776742
Drug: Sequential fluoroscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential fluoroscopy guidance
Study: 30679232
Drug: HMG-CoA reductase
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitor or blocking antibody against proprotein convertase subtilisin/kexin type 9
Study: 23713297
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy combined with rehabilitation training
Study: 20126902
Drug: TR+ (non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR+ (non-surgical periodontal treatment)